News Hub | News Direct
Back

BX+-+168+-+2+泵吸式便携式六合一气体检测仪+厂家


Article thumbnail News Release

Mariner Expands Independent Platform Leadership Team Amid Surge in Advisor Demand

Mariner

Mariner, a national financial services firm, is reaffirming its strategic commitment to the independent advisor channel with the continued expansion of Mariner Independent, the firm’s supported independence platform. Serving more than 1,100 advisors and overseeing approximately $40 billion in assets under management (AUM) and assets under advisement (AUA), Mariner Independent is a core driver of the firm’s growth strategy. As demand accelerates flexible affiliation models and long-term monetization pathways, the firm is enhancing its leadership team to support the next phase of platform evolution. In doing so, Mariner has named Rob Sandrew as Head of Mariner Independent to guide the platform’s ongoing innovation, advisor experience, and expansion into new partnership models. Sandrew brings a unique blend of operational and strategic leadership; prior to joining Mariner, he served as chief growth officer at Integrated Partners, where he helped grow the firm from $3 billion to over $21 billion in assets. In addition to Sandrew, Verne Marble recently joined Mariner Independent as Managing Director. Marble brings a wealth of experience in distribution and leadership, having held senior positions at Private Advisor Group, LPL Financial, and Edelman Financial Engines. “This is a pivotal time for independent advisors, and I’m proud to be stepping into a leadership role at Mariner Independent as it enters its next stage of growth,” said Sandrew. “We have a real opportunity and the capabilities to deepen the support and flexibility advisors are looking for, and I’m eager to help shape a platform that truly aligns with where both the industry and advisor expectations are heading.” These leadership appointments come during a period of robust growth for Mariner as the firm expands its independent offerings, including appealing buyout options for affiliated 1099 advisors seeking succession solutions. Recent transactions, such as the acquisition of Ocean Heights Advisors, provide advisors with an opportunity to monetize their practice while transitioning into a comprehensive W-2 structure that includes bespoke terms, upfront cash, and equity, along with a three-year earnout based on operating margins. “We’ve seen tremendous growth from our independent advisors, and it’s a clear signal that the model is working. Advisors want the freedom to run their business their way, with the support to scale and the options to monetize when the time is right,” said Marty Bicknell, CEO and president of Mariner. “That’s exactly what Mariner Independent is built to deliver. With Rob and Verne stepping in, we’re expanding that vision and setting the pace for what’s next in the independent space. Their leadership ensures Mariner Independent will continue to be a destination for growth-minded professionals who want to remain independent without feeling alone.” Since its launch in 2020, Mariner’s supported independence model has delivered a robust suite of services including back-office support, practice management, marketing, investment solutions, and compliance resources, all backed by a dedicated team of over 300 professionals. Sandrew and Marble will both join the Mariner Independent Executive Committee, partnering with the firm’s leadership to shape the future direction of this dynamic platform. About Mariner Mariner is a privately held national financial services firm equipped with the experience to meet your modern wealth needs. Our advisors have access to in-house expertise covering everything from tax, estate, trust, and insurance to investment banking and valuation, so they can maximize time spent creating unified wealth plans with clients. By opening more windows of wealth, we can create opportunities to positively impact the lives of many. With this purpose, we intend to raise the bar for the entire industry. Founded in 2006 with $300 million in assets under advisement, Mariner and its affiliates now advise on nearly $555 billion in assets which includes assets under advisement and assets under management as of 3/31/25. Learn more at www.mariner.com Contact Details Hot Paper Lantern Remi Yuter mariner@hotpaperlantern.com Company Website https://www.mariner.com/

June 17, 2025 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

BiomX Stock Could Soar 3000% As This $10M Biotech Cracks The 'Superbug' Code, Wall Street Says

Global Markets News

BiomX Inc. (NYSE: PHGE)* has achieved what Big Pharma couldn't accomplish in over 20 years — successful clinical trials using viruses to treat life-threatening infections that no longer respond to antibiotics. The $10 million biotech has reported positive Phase 2 results in diabetic foot bone infections, a condition so challenging that no new drugs have been approved for it in two decades. Meanwhile, their cystic fibrosis program showed 14% of patients completely cleared chronic lung infections after just 10 days of treatment. Approximately 160,000 lower limb amputations occur annually in diabetic patients in the U.S., with 85% caused by diabetic foot infections or diabetic foot osteomyelitis — creating an $8 billion annual healthcare burden according to company data. Current treatments rely on antibiotics that increasingly fail due to resistance, often leaving amputation as the only option. Clinical Breakthroughs Across Two Major Programs BiomX's March 2025 Phase 2 results in diabetic foot osteomyelitis from 41 patients delivered notable outcomes. The company achieved statistically significant percent area reduction of ulcer size, with p-values of 0.046 at week 12 and 0.052 at week 13. The treatment showed separation from placebo starting at week 7, with differences greater than 40% by week 10. BiomX also demonstrated statistically significant improvements in ulcer depth and reducing ulcer area expansion, while BX211 was safe and well-tolerated throughout the study. The company's cystic fibrosis program has been equally impressive. In their Phase 1b/2a study, 14.3% of patients converted to sputum culture negative for P. aeruginosa after 10 days of treatment, compared to 0% in the placebo group. One patient had been infected for 35 years before achieving complete clearance. The FDA has granted this program both Fast Track designation and Orphan Drug Designation, potentially accelerating the approval pathway. BiomX's approach uses bacteriophages — viruses that naturally target and kill specific bacteria — instead of traditional antibiotics that bacteria can develop resistance against. The company has overseen more than 50 compassionate use cases with no significant side effects to date. Military Validation and Wall Street's Bullish Take The U.S. Defense Health Agency has provided $40 million in non-dilutive funding to BiomX's diabetic foot program, representing significant validation of the technology. "They're seeing soldiers coming out of the Ukraine war with extremely antibiotic-resistant infections," CEO Jonathan Solomon said during the company's May 2025 earnings call. Despite the clinical progress and military backing, BiomX trades at approximately $10 million market cap — a disconnect0 that has caught Wall Street's attention. H.C. Wainwright maintains a Buy rating with a $15 price target, representing potential upside of over 3000% from recent levels around $0.4 Laidlaw & Company rates the stock Buy with a $16 price target, suggesting almost 4000% upside potential. Laidlaw analyst Yale Jen called the recent data "an absolutely positive surprise" and characterized BX211 as "a high value and clinically de-risked asset." The analysts' optimism stems from the clinical validation across both programs, massive addressable markets, and limited competition in the phage therapy space. Major Catalysts on the Horizon BiomX estimates addressable markets exceeding $2.5 billion globally for their diabetic foot program and $1.6 billion for cystic fibrosis based on patient populations and potential pricing benchmarks. The company expects to have sufficient funding through Q1 2026, aligning with anticipated BX004 Phase 2b results in cystic fibrosis. Key upcoming catalysts include the Phase 2b readout for their cystic fibrosis program expected in Q1 2026, ongoing Phase 2/3 trial discussions with the FDA for their diabetic foot program, and potential regulatory meetings in the second half of 2025. The company is also exploring partnership opportunities as the phage therapy space attracts increasing attention from large pharmaceutical companies. With validated clinical data, military funding, and Wall Street price targets suggesting potential returns exceeding 3000%, BiomX could offer investors exposure to phage therapy as a potential new approach to treating antibiotic-resistant infections. As the global antibiotic resistance crisis intensifies, the company's nature-based approach to killing bacteria positions it at an interesting inflection point in infectious disease treatment. BiomX shares were trading at ~$0.4 at last check Recent News Highlights from BiomX BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) * Legal Disclaimer & Disclosure: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by Wall Street Wire™. The operators of Wall Street Wire, arx advisory, are not registered brokers, dealers, or investment advisers. This report contains and is a form of paid promotional content or advertisement for BiomX Inc and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by BiomX Inc prior to publication. The operators of wall street wire have received or are expected to receive a monthly recurring fee of five thousand united states dollars via wire transfer from BiomX as part of an ongoing agreement starting June 1st, 2025 in return for social media distribution and promotional coverage services, and receive additional compensation for non promotional unrelated data and advisory services on top of that. They do not hold any shares in BiomX. Please review the full disclaimers and compensation disclosures here for further details: redditwire.com/terms. We are not responsible for the price targets mentioned in this article nor do we endorse them, they are quoted based on publicly available news reports believed to be reliable and additional or price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details News Coverage ronald@futuremarketsresearch.com

June 16, 2025 07:04 PM Eastern Daylight Time

Article thumbnail News Release

$USD1 Stablecoin Begins Minting on TRON

TRON DAO

Geneva, Switzerland, June 12, 2025 – TRON DAO, the community-governed DAO dedicated to accelerating the decentralization of the internet through blockchain technology and decentralized applications (dApps), has announced the first minting of the USD1 stablecoin on the TRON blockchain. Released by World Liberty Financial., the developer of a pioneering DeFi protocol and governance platform inspired by President Donald J. Trump, USD1 is 100% backed by short-term US government treasuries, US dollar deposits, and other cash equivalents. The minting of WLFI’s stablecoin on TRON confirms an announcement made last month at Token2049 in Dubai by Eric Trump, executive vice president of the Trump Organization and co-founder of WLFI. Trump announced in May that USD1 was the stablecoin selected to settle MGX’s $2 billion investment in Binance, quickly followed by a supporting statement that USD1 will be fully integrated into the TRON ecosystem. The minting kicked off in the early morning hours of June 11, documented by an X post from TRON founder Justin Sun, who described this milestone as a “giant leap for stablecoins.” “From launching new ideas to challenging how we think about money and freedom, it’s clear that we are making progress in moving the crypto industry forward,” said Sun. “It has been great to be part of this process with WLFI and to see the Trump administration taking steps to create a clearer and more supportive environment for innovation.” The integration of USD1 as an independent and secure stablecoin strengthens the TRON ecosystem while advancing their ongoing mission to promote economic growth. By offering the transparency and security that institutions demand, USD1 positions TRON for even broader institutional adoption. WLFI's strategic decision to mint USD1 on TRON signals a growing trust in the network's robust infrastructure and demonstrates increasing institutional confidence in TRON’s ability to deliver secure, scalable blockchain solutions for global markets. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON blockchain has experienced significant growth since its MainNet launch in May 2018. TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin, exceeding $78 billion. As of May 2025, the TRON blockchain has recorded over 312 million in total user accounts, more than 10 billion in total transactions, and over $22 billion in total value locked (TVL), based on TRONSCAN. TRONNetwork | TRONDAO | X | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Yeweon Park press@tron.network Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

June 12, 2025 08:24 PM Eastern Daylight Time

Image
Article thumbnail News Release

Apples & Bananas Launches Globally: A Learning App Built on the Whole-Child Approach for Ages 0–8

Apples & Bananas

Apples & Bananas, a thoughtfully designed, smart and simple, all-in-one learning app for children aged 0–8, is now available on iOS and Android. Purpose-built to support and supplement school readiness through play, the app combines classroom learning, creative exploration, calming activities, and off-screen time—empowering children to learn and grow at their own pace in a safe, inclusive environment. Poised to become the #1 early learning app for families globally, Apples & Bananas is kid-safe by design and built to meet what today’s parents are really looking for: a trusted, inclusive space that helps children learn, grow, and thrive—without overwhelming them or worrying parents. It brings together structured and unstructured learning, creativity, and co-play, all at a pace that’s right for each child. Created by education experts and a passionate team of parents, designers, and storytellers, the app is built to grow with your child—offering personalized experiences for ages 0–2, 2–4, 4–6, and 6–8. “We’re parents too—and we’ve seen first-hand how hard it is to find something that’s educational, safe, fun, and grows with your child,” says Uday Phoolka, Founder and Creator of Apples & Bananas. “This app is designed to be the one place you can turn to for it all—whether it’s learning numbers, listening to a calming story, or exploring their creativity with music and play.” What Makes Apples & Bananas Different: Whole-child development: Supports cognitive, motor, emotional, mindfulness, and creative skills through a mix of guided learning and free exploration. Kid-safe and inclusive: No ads. No distractions. Built from the ground up to reflect today’s diverse world and ensure every child feels seen and celebrated. All-in-one learning: From math, reading, music, and language to interactive games, calming stories, and hands-on activities—everything is in one place. Balanced screen time: Encourages off-screen moments with audiobooks, bedtime stories, and read-alouds that foster imagination and language development. Supports Social-Emotional Growth: With engaging videos, read-alongs, and lovable characters, kids learn to understand feelings, build empathy, and navigate friendships—gently and playfully. Co-play and connected parenting: Grown-ups are invited too—with progress tracking, suggestions for co-playing, and insights that strengthen the parent-child bond. Paced for each child: Structured and unstructured learning levels— 0–2, 2–4, 4–6, and 6–8 —that adapt to a child’s pace, so no one is rushed and no one is held back. Made for families everywhere: Whether you're in the USA, Europe, or Asia, Apples & Bananas is designed to be easy to use, culturally inclusive, and globally accessible. “Parents today want more than just screen time fillers—they want digital experiences that are thoughtful, safe, and truly supportive,” adds Uday. “ Apples & Bananas is about helping children thrive, while giving parents peace of mind and a little breathing room.” Apples & Bananas is now available to download worldwide on: iOS App Store Google Play Store About Apples & Bananas Created by educators, designers, and child development experts, Apples & Bananas is an edtech platform that believes in school readiness through play. The app empowers children ages 0–8 with age-appropriate learning across subjects, builds real-world skills, and strengthens family connections—making it the ultimate early learning companion for the modern parent. About USP Digital USP Digital is a global leader in children's digital content, dedicated to creating joyful, engaging, and educational experiences for toddlers and pre-schoolers. With a rich catalog of over 70 original IPs — including Bob the Train, Farmees, Junior Squad, Super Supremes, Boom Buddies, and Apples and Bananas — the company has built vibrant, memorable worlds that children love and families trust. Many of these beloved characters have grown alongside their young audiences, evolving while continuing to inspire curiosity, creativity, and learning through play. Founded by Uday Phoolka in 2013, USP Digital has produced tens of thousands of videos in over 44 languages, garnering over 250 billion views globally. Today, the company continues to shape the landscape of children’s edutainment across a wide range of digital platforms reaching millions of families every day. Contact Details USP Digital Jaskirat Kabir Singh Gill +91 99588 97584 kabir@uspdigital.co Company Website https://www.applesandbananas.co/

June 10, 2025 10:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

Medicus Pharma Ltd. (NASDAQ: MDCX) Positioned for Growth in a $5 Trillion Biotech Market

Medicus Pharma Ltd (MDCX)

The global population is aging rapidly, with the number of people aged 65 and older expected to double by 2050. This demographic shift is driving a surge in chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. At the same time, breakthroughs in biomedical research are enabling the development of targeted, more effective therapies, transforming treatment approaches in both human and veterinary medicine. These twin forces, rising demand fueled by aging and disease prevalence along with technological innovation, are propelling unprecedented growth across biopharma markets. The global biotechnology sector is projected to expand from $1.74 trillion in 2025 to over $5 trillion by 2034, representing a compound annual growth rate (CAGR) of 12.5 percent. Specialty pharmaceuticals, including biologics and novel drug delivery systems, are expected to grow even faster, with forecasts predicting a 26.5 percent CAGR over the same period. Oncology remains a key driver, with spending on cancer medicines forecasted to nearly double from $252 billion in 2024 to $441 billion by 2029. Meanwhile, veterinary oncology is emerging as a high-potential frontier, with the U.S. market alone projected to reach $1.48 billion by 2030, driven by rising pet ownership and demand for advanced care. The urology therapeutics segment also shows steady growth potential, expected to rise from $10.5 billion in 2024 to $15.8 billion by 2033. Amid this expansive and interconnected landscape, Medicus Pharma Ltd. (NASDAQ: MDCX) is methodically positioning itself to capitalize on these powerful market tailwinds. Through a diversified portfolio of innovative drug delivery platforms and targeted therapies, Medicus addresses some of the most pressing health challenges across human and veterinary medicine. Medicus Pharma: Methodically Building a High-Leverage Growth Story Though still flying under many investors’ radars, Medicus Pharma is rapidly assembling the elements of a high-leverage growth story. On June 2, the company completed a $7 million public offering, selling 2,260,000 units at $3.10 each. Each unit includes one common share plus one warrant exercisable at the same price over five years. The capital will primarily fund a Phase 2 proof-of-concept trial in basal cell carcinoma (BCC) using Medicus’s flagship doxorubicin-loaded dissolvable microneedle patch (D-MNA). Additional funds may support broader development in non-melanoma skin cancers or other pipeline programs. Strategic Veterinary Expansion: FDA Submission for Equine Squamous Cell Carcinoma This timely financing was quickly followed by a major regulatory milestone. On June 9, Medicus announced submission of a formal product development plan to the U.S. FDA for a veterinary application of D-MNA targeting equine squamous cell carcinoma (SCC). The program is advancing under an Investigational New Animal Drug (INAD) file, aiming for conditional approval. It leverages the same microneedle patch technology used in human dermatologic trials, demonstrating a strategic effort to repurpose clinical data and technology across human and veterinary markets. Tapping an Untapped Veterinary Oncology Opportunity The equine indication represents a significant market opportunity. As CEO Dr. Raza Bokhari highlighted, “In veterinary medicine, where only a handful of oncology drugs are approved, developing a non-invasive treatment for equine SCC targets a largely unmet need, a potential $250 million market.” The planned study will enroll 50 horses across five U.S. sites in a placebo-controlled design, comparing two D-MNA doses against placebo, with tumor response assessed at day 90. Medicus has secured FDA Minor Use in Major Species (MUMS) Designation, which grants seven years of market exclusivity upon approval, a valuable commercial advantage in a segment with limited competition. D-MNA Platform: Promising Safety and Efficacy Data The D-MNA patch, originally developed for human skin cancers, is supported by encouraging early data. A Phase 1 trial in Australia (SKNJCT-001) involving 13 patients with nodular BCC showed the treatment was well tolerated with no dose-limiting toxicities. Remarkably, 46 percent of lesions achieved complete histological clearance after a single application, an impressive result given the minimally invasive delivery. This platform delivers doxorubicin directly into the dermis through a biodegradable microneedle array, minimizing systemic exposure while concentrating the drug’s effect at the tumor site. Expanding Clinical Trials Across Continents Building on this foundation, Medicus is running two Phase 2 trials. In the U.S., the SKNJCT-003 study recently expanded enrollment from 60 to 90 patients following a positive interim analysis that showed over 60 percent clinical clearance. This multicenter, placebo-controlled trial compares the patch to the standard of care, with European sites now joining due to growing investigator interest. Concurrently, the SKNJCT-004 trial in the United Arab Emirates involves 36 patients across four hospitals, including Cleveland Clinic Abu Dhabi, targeting both histological and clinical clearance endpoints. Strategic Acquisition: Entering Late-Stage Urology Complementing its internal pipeline, Medicus is also positioning itself as a consolidator of high-value assets. In April, the company signed a binding letter of intent to acquire UK-based Antev Ltd., whose lead candidate, Teverelix, is a GnRH antagonist in late-stage development for two urology indications: acute urinary retention (AUR) due to benign prostatic hyperplasia and hormone-sensitive prostate cancer in patients at elevated cardiovascular risk. These combined markets represent a $6 billion annual opportunity, and Teverelix has completed multiple clinical trials in Europe. Under the deal, Antev shareholders would receive approximately 19 percent of Medicus’s post-merger equity, plus up to $65 million in milestone payments tied to regulatory and commercial successes. A Platform With Multiple Growth Levers Together, Medicus offers optionality and platform leverage across human oncology, veterinary medicine, and dermatology, all fields marked by limited innovation and strong pricing power. Its lead asset is already in Phase 2 with international trial sites and active FDA engagement. The veterinary program offers a faster commercialization path with fewer regulatory barriers, while the Antev acquisition could propel Medicus into late-stage, multi-billion-dollar indications. Why Investors Should Watch MDCX Medicus Pharma (NASDAQ: MDCX) paints the picture of a small-cap biotech transitioning from concept to execution. The recent capital raise was non-dilutive and immediately followed by a key regulatory filing. Clinical trials across humans and animals are expanding, and a transformative acquisition is imminent. With a methodical approach tying together clinical progress, intellectual property, and market strategy, Medicus is quietly building momentum, making MDCX a stock to watch closely in the second half of 2025. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by MDCX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

June 10, 2025 10:20 AM Eastern Daylight Time

Article thumbnail News Release

EDGE Boost Launches Social Accountability Program, Adding Peer-Based Accountability to its Roster of Responsible Gaming Tools

EDGE Boost

EDGE Markets, the company behind EDGE Boost, one of the first debit cards designed specifically for responsible gaming, today announced the launch of its newest responsible gaming feature: a co-pilot system for social accountability. Through the EDGE Boost platform, users can nominate trusted friends or family to receive weekly reports of their transactions and participate in real-time limit adjustments, creating a shared commitment to more responsible play. Social accountability leans on a core behavioral insight that accountability works best when it comes from someone you know, not a faceless platform or app. Early adoption of the co-pilot system has already exceeded expectations with 7% of EDGE Boost users enabling the feature, far surpassing the industry standard of 1-2% adoption for similar, operator-based responsible gaming tools. “The reason why the co-pilot feature has been so successful is peer involvement,” said Seni Thomas, Founder and CEO of EDGE Boost. “Social accountability is why having a gym buddy works. By involving a buddy in your betting lifestyle, one is set up even better for responsible play. We have always said that EDGE Boost’s mission is to provide a safer and more responsible environment for users to engage with gaming and we know social accountability is doing just that.” Co-pilots will receive weekly snapshots of a user’s EDGE Boost transactions. If a user attempts to raise their deposit or spending limits, a co-pilot must enter a verification code before the change can take effect. The new feature aligns with the American Gambling Association’s (AGA) evolving Responsible Gaming Code of Conduct. Social accountability also helps foster responsible gaming by avoiding punitive approaches and reducing negative stigma. The co-pilot feature is now live and available to all EDGE Boost users. About EDGE Boost EDGE Boost is the responsible financial platform for smart bettors. One of the first deposit accounts built exclusively for betting-related use, held with Cross River Bank, Member FDIC, and eligible for FDIC insurance up to $250,000 per depositor. As a neutral, third party, EDGE Boost provides financial segmentation and a holistic view to bettors for all their financial betting data, with custom tools, like personalized spending limitations and cashback incentives, available to help all bettors be more responsible. Customers experience frictionless, instant free betting that is compatible with almost any online or physical betting platform. *Deposit Checking accounts are held with Cross River Bank, Member FDIC. The Edge Boost Visa Debit Card is a Visa® debit card issued by Cross River Bank, Member FDIC, pursuant to a license from Visa U.S.A. Inc. The Edge Boost Visa Debit Card is not available to all residents of U.S. territories. For further information, please see our Terms of Service and Cardholder Agreement. If you think you or someone you know may have a gaming problem, call 1-800-GAMBLER. Contact Details Sterling Randle srandle@hotpaperlantern.com Company Website https://www.edgeboost.bet/

June 10, 2025 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Top Crypto Stocks Driving the Future of Digital Finance

MATH COIN MSTR MTPLF

Institutional capital is moving deeper into the digital asset ecosystem, accelerating the convergence between traditional finance and crypto markets. The global crypto exchange market was valued at approximately $24.6 billion in 2024 and is expected to exceed $75 billion by 2029. Trading volume in crypto derivatives now makes up nearly 80 percent of all activity in the space, a sharp increase from just a few years ago. Meanwhile, stablecoins have surpassed $160 billion in total market capitalization, with growing use cases across lending, payments, and decentralized finance. Perhaps more importantly, institutional sentiment has shifted. A recent survey by Fidelity Digital Assets showed that 71 percent of institutional investors plan to increase their allocation to digital assets in the near term. The percentage of asset managers and pension funds seeking crypto exposure through listed equities has also grown substantially, particularly in jurisdictions with more regulatory clarity. This shift is not just about Bitcoin’s price. It reflects a broader recognition of digital infrastructure as a strategic asset class. A new equity segment is emerging that bridges both worlds. These companies operate at the intersection of capital markets and crypto, monetizing demand for trading, custody, liquidity, derivatives, and treasury access. Unlike pure-play miners or speculative token projects, these firms are building platforms, generating recurring revenue, and leveraging volatility instead of being crushed by it. Several names are beginning to draw increased investor attention for how they are positioned within this fast-evolving space. Let’s take a closer look at a few that are capturing both institutional flows and long-term strategic interest. Metalpha (NASDAQ: MATH) may not be the most well-known name in the crypto space, but that is quickly changing. This digital asset wealth management company is posting numbers that few can ignore, and its business model sets it apart from the usual suspects in the Bitcoin-related equity space. Founded in 2015 and listed on the Nasdaq in 2017, Metalpha has evolved into a powerhouse in institutional-grade digital asset management. Its subsidiaries offer global private wealth management services linked to virtual assets, tailored to high-end clients including exchanges, mining firms, investment funds, and family offices. With top talent from Wall Street and strategic backing from Bitmain and Antalpha Technologies, Metalpha has become one of Asia’s largest crypto derivatives players. In a February announcement, the company revealed a pivotal partnership with Gewan Holding and Zodia Markets to form ZMG7 LLC. The new joint venture will drive digital asset infrastructure growth in the Middle East, centered in the UAE. Gewan brings regional influence and investment experience, while Zodia Markets—backed by Standard Chartered—adds international credibility. With this move, Metalpha is entering a key global hub just as institutional interest in crypto surges in the Gulf region. What has truly caught investors’ attention, however, is Metalpha’s most recent financial performance. For the six months ended September 30, 2024, the company posted total revenue of nearly $19.72 million, up almost fourfold from the $5.08 million reported a year earlier. Net income flipped from a loss of $3.85 million to a profit exceeding $6 million. This turnaround is not a fluke. It follows sustained growth, with prior half-year results in March 2024 already showing a jump to $11.68 million in revenue. In just one year, Metalpha has gone from struggling to thriving. To reinforce its bullish stance, the company also announced a $5 million share repurchase program, aimed at returning value to investors over the next 36 months. Buybacks of this nature, especially in the microcap world, are often signs of confidence. Metalpha is signaling that it believes its stock is undervalued. CEO Adrian Wang put it plainly. The company has been investing not just in revenue-driving products but also in foundational elements like internal controls, top-tier talent, and technology infrastructure. These are the kinds of quiet investments that do not show up in earnings headlines but make a company scalable and durable. Many retail investors may not have heard of Metalpha. That may not last. According to a recent analysis from CRG, the company’s full-year FY2025 results are expected in June and could bring revenue between $60 and $80 million and net income between $18 and $24 million. If these numbers materialize, it could justify a major re-rating of the stock. As it stands, Metalpha trades at a significant discount to peers like MicroStrategy and Marathon Digital Holdings, despite generating recurring revenue and avoiding the heavy overhead that burdens traditional mining firms. This is not just a Bitcoin play. Metalpha profits from market volatility through its derivatives offerings, regardless of whether prices are rising or falling. It does not need to liquidate assets to stay afloat, nor does it rely on pure speculation. It offers exotic structured products that allow clients to hedge, speculate, and invest with far more nuance than just buying and holding crypto. Through its relationship with Bitmain, Metalpha even gains access to Bitcoin at wholesale prices. That operational edge, combined with its licensing under Hong Kong’s rigorous regulatory framework, creates a compelling case for institutional investors who want exposure to crypto with compliance and control. The broader trend is also in its favor. Institutional crypto derivatives are a growing sector. More investors are demanding tools that reflect those found in traditional finance. Metalpha is meeting that demand head-on with a full suite of products, global partnerships, and a compliance-first approach. With its latest venture in the UAE, it is extending that reach into yet another strategic region. The technical setup is strong, the financials are improving quarter by quarter, and the management team is aggressively positioning the firm for global growth. Add a buyback program and potential near-term catalysts like the upcoming annual report, and you have a stock that could move quickly if it gets discovered by more investors. For a deeper breakdown of why Metalpha may be the most asymmetric crypto finance opportunity in the market, this piece offers further insights: The Sleeping Crypto Derivatives Giant Set to Wake. Metalpha (NASDAQ: MATH) may not stay under the radar for much longer. There could be a significant upside for those who are paying attention now. Metaplanet (OTC: MTPLF) has quickly emerged as Japan’s most aggressive and visible corporate advocate for Bitcoin adoption. As the country’s first Bitcoin Treasury Company, Metaplanet has made Bitcoin the foundation of its corporate strategy and treasury operations. Since adopting its Bitcoin treasury policy in April 2024, the firm has pursued an accumulation path that is transforming its position in both Japan’s financial markets and the global digital asset ecosystem. On June 2, 2025, Metaplanet announced the purchase of 1,088 additional bitcoin, bringing its total holdings to over 8,888 BTC. This latest acquisition cost the company approximately 16.885 billion yen, or $117.5 million, with an average purchase price of $108,051 per bitcoin. That positions the firm’s total bitcoin holdings at over $930 million in value. The purchase was funded through capital raised via the issuance of zero-interest bonds, a financing method the company has repeatedly used to expand its BTC exposure without equity dilution. Metaplanet’s year-to-date BTC purchases now total 7,126 BTC, with a stated goal of reaching 10,000 BTC by the end of 2025. The company reported a year-to-date BTC yield of 66.3 percent and a BTC gain of 2,684 BTC. Translated into fiat terms, that BTC gain is worth approximately 40.5 billion yen. These figures underscore the success of Metaplanet’s financial engineering and its commitment to extracting performance from its Bitcoin-centric model. Market recognition of this approach has surged. On June 3, 2025, Metaplanet became the heaviest and largest stock on the Japanese stock market by trading value, with shares turning over ¥222 billion, or roughly $1.51 billion, in a single session. The company sold 170 million shares during the day, an event that marked a pivotal shift in Japanese capital markets toward Bitcoin-oriented firms. This move followed news of the Vanguard Developed Markets Index The fund acquired 2.64 million shares for $7.46 million, a sign that institutional appetite for Metaplanet’s equity is growing alongside its BTC reserves. Financially, Metaplanet is posting strong operating results to match its Bitcoin strategy. The company reported Q1 FY2025 operating profit of ¥593 million, an 11 percent increase from the previous quarter. Revenue reached ¥877 million, up 8 percent quarter-over-quarter, with 88 percent of that revenue attributed to income generated from Bitcoin. This blend of capital markets agility, operational performance, and conviction in Bitcoin has made Metaplanet one of the most watched Bitcoin treasury companies in the world. Its ambition to reach five-figure BTC holdings while attracting global capital sets it apart as a uniquely positioned firm in both the Japanese and global crypto equity space. Coinbase (NASDAQ: COIN) is positioning itself as a core institution in the evolving global financial system by driving utility, expanding infrastructure, and increasing access to crypto across both individual and institutional markets. In the first quarter of 2025, Coinbase reported $2.0 billion in total revenue and $930 million in adjusted EBITDA. Transaction revenue came in at $1.3 billion, while subscription and services revenue approached $700 million, driven largely by the rise in stablecoin activity and growth in Coinbase One. The company’s strong liquidity position, with $9.9 billion in USD resources, provides a foundation for long-term expansion. Coinbase has been advancing its roadmap for 2025 by gaining global market share in both spot and derivatives trading. USDC, the second-largest dollar-backed stablecoin, reached a record market cap of over $60 billion, supported by increased adoption from both retail and institutional users. New product offerings and acquisitions continue to extend Coinbase’s platform capabilities. Bitcoin-backed USDC loans have strengthened financial utility, while purchases of Spindl and Iron Fish are improving Base’s privacy and usability. Coinbase One continues to scale, offering features like zero trading fees, enhanced staking rewards, and free gas on Base, helping to build customer loyalty. On the legal and policy front, Coinbase achieved several major wins. The dismissal of the SEC lawsuit marked a significant shift toward fairer oversight, while the directive to establish a Strategic Bitcoin Reserve recognized Bitcoin’s status as a national strategic asset. Coinbase’s advocacy efforts are helping to shape the regulatory environment in a way that supports innovation and protects users. Coinbase also recently announced its agreement to acquire Sentillia B.V., the parent company of Deribit, the world’s leading crypto options exchange. The deal, valued at approximately $2.9 billion, includes $700 million in cash and 11 million shares of Coinbase stock. The acquisition is expected to close by the end of the year and would significantly expand Coinbase’s presence in crypto derivatives, adding both diversity and durability to its revenue streams. Looking ahead, Coinbase is focused on growing subscription revenue, increasing real-world crypto utility, and scaling its infrastructure. In April alone, the company generated $240 million in transaction revenue. Second quarter guidance points to $600 to $680 million in subscription and services revenue, even with a projected decline in blockchain rewards due to asset price pressures. With ongoing improvements to its trading platform, Base network, and institutional tools, Coinbase remains a leading name in the Bitcoin-linked equity space. MicroStrategy (Nasdaq: MSTR) has firmly established itself as the world’s first and largest Bitcoin Treasury Company, turning its corporate strategy into a bold bet on the long-term value of Bitcoin. Through a combination of equity raises, debt offerings, and reinvested cash flows, MicroStrategy continues to amass a staggering Bitcoin reserve while delivering shareholders direct exposure to the leading digital asset. As of late May 2025, the company holds approximately 580,250 BTC after raising $427 million and acquiring 4,020 additional coins. Its capital markets activity remains aggressive and diverse. MicroStrategy executed a record $21 billion at-the-market equity offering in Q1 2025 and completed two preferred stock IPOs widely regarded as among the most successful in a decade. The company’s financial strategy now includes the issuance of both Perpetual Strike and Perpetual Strife Preferred Stock, raising hundreds of millions in fresh capital. Additional proceeds from ongoing ATM programs continue to fuel Bitcoin purchases and working capital. Despite reporting a Q1 2025 loss from operations of $5.9 billion, largely due to unrealized digital asset revaluations under new fair value accounting rules, the company still ended the quarter with over $60 million in cash. The adoption of the new accounting standard added a $12.7 billion uplift to retained earnings and allows for greater transparency into asset volatility. MicroStrategy's "BTC Yield" reached 13.7% year-to-date by late April, nearing its increased 2025 target of 25%. The company also reported a year-to-date "BTC $ Gain" of $5.8 billion, reflecting strong execution and market tailwinds. As of March 31, its 528,185 BTC had a market value of $43.5 billion, up from a cost basis of $35.6 billion. Beyond its Bitcoin exposure, MicroStrategy continues to generate over $100 million in quarterly revenue through its enterprise software business, with significant growth in subscription services. However, other software segments showed year-over-year declines, and gross profit margins narrowed slightly to 69.4%. MicroStrategy remains one of the few publicly traded vehicles offering direct institutional-scale exposure to Bitcoin. With an aggressive treasury strategy, innovative capital formation, and a growing digital asset footprint, the company positions itself as a key lever for investors bullish on Bitcoin’s long-term trajectory. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Global Industrial Solutions to assist in the production and distribution of this content related to MATH. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

June 10, 2025 06:00 AM Eastern Daylight Time

Article thumbnail News Release

Justin Sun Takes Center Stage at Bitcoin Vegas 2025 with TRON DAO as Top Sponsor of Code + Country and Co-Host of Kraken’s Oceanic Night

TRON DAO

Geneva, Switzerland, June 2, 2025 — TRON DAO, the community-governed DAO dedicated to accelerating the decentralization of the internet through blockchain technology and decentralized applications (dApps), participated in Bitcoin 2025, which took place May 27-29 in Las Vegas. TRON DAO kicked off the week as a top tier sponsor for Code + Country's America 250 VIP Reception on May 27 at AYU Dayclub. This exclusive VIP experience hosted key political figures and leading voices in Bitcoin, AI, energy and technology, creating unparalleled opportunities for high-impact networking. Over 800 guests were in attendance, positioning TRON at the center of conversations shaping America's technological future. Highlighting day one of the conference, Justin Sun, Founder of TRON and Advisor of WBTC, participated in the high-profile panel "Building The Future Financial Products of America" on the Nakamoto Stage. Hunter Horsley (CEO, Bitwise Asset Management) and Mike Belshe (CEO, BitGo) also joined Sun as speakers. Hosted by Kevin Kelly (CEO, Kelly Intelligence), the panel explored how blockchain technology and digital assets are reshaping traditional financial products for investors and institutions in the United States. “We are going to see a lot more products that blend blockchain with traditional finance,” said Sun, “Kraken’s plan to offer tokenized versions of U.S. stocks and ETFs is a perfect example. This kind of blockchain integration across finance feels inevitable.” On May 28, Sun also made an appearance at the ‘Whales & Insiders: BTCFi and New Yield Opportunities’ event hosted by MetaEra for a keynote session titled “TRON as the Global Settlement Layer.” Sharing the stage with top minds to drive conversations to frontier Bitcoin DeFi innovations. Thereafter, TRON DAO concluded day two as co-host of Kraken's Oceanic Night Party, welcoming over 500 attendees including key ecosystem collaborators and visionaries from across the crypto industry. TRON DAO concluded the week by connecting with a prominent industry voice as Sun joined Ross Ulbricht and his family at the table for Ulbricht's Welcome Back Luncheon, showing support to the Bitcoin community. TRON's commanding presence at Bitcoin Vegas 2025 coincides with a period of remarkable growth for the network. Having recently surpassed the significant milestone of $77.7 billion in circulating supply of Tether (USDT), TRON has established itself as the leading blockchain for Tether globally. This reinforces TRON's position as a dominant force in the greater blockchain and digital asset landscape. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON blockchain has experienced significant growth since its MainNet launch in May 2018. TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin, exceeding $77.7 billion. As of May 2025, the TRON blockchain has recorded over 309 million in total user accounts, more than 10 billion in total transactions, and over $23.5 billion in total value locked (TVL), based on TRONSCAN. TRONNetwork | TRONDAO | X | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Yeweon Park press@tron.network Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

June 02, 2025 04:02 PM Eastern Daylight Time

Image
Article thumbnail News Release

Inspira Technologies Receives $2 Price Target and Buy Rating: Everything You Need to Know

Global Markets News

Litchfield Hills Research has initiated coverage of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN)* with a Buy rating and a $2 price target, representing potential upside of over 225% from current trading levels of around $0.61 per share. This bullish outlook comes as the medical technology company continues to critical care technology addressing what the analyst describes as "a medical need without good options." The analyst notes that mechanical ventilators are "WWII technology in desperate need of an upgrade" with reports showing that 30% to 50% of ICU patients don't survive. Unlike mechanical ventilation, Inspira's ART500 technology would enable patients to remain awake during treatment while stabilizing oxygen levels without intubation and coma. What distinguishes Inspira from typical early-stage medical device companies is its proven regulatory execution and early commercial success. The company's first generation technology, the INSPIRA ART100 system, received FDA clearance in May 2024 and is already deployed in leading U.S. hospitals. The excitement around this technology reached a new high in April 2025 when the first successful patient treatment was completed at Westchester Medical Center. The commercial momentum seems to be accelerating. Inspira announced it received payment in the "low hundreds of thousands of dollars" from its U.S. distributor for delivered systems, marking the company's first revenues. CEO Dagi Ben-Noon called this "a transformative milestone for Inspira as we establish our presence in the U.S. medical landscape." The company has now initiated global commercial rollout discussions and expects additional deliveries in the second half of 2025. Central to Inspira's technology platform is the AI-powered HYLA blood sensor, which recently achieved 96% accuracy in clinical studies at Sheba Medical Center, one of the world's top hospitals. The system provides continuous monitoring without requiring blood draws, targeting the blood gas analyzer market projected to reach $5.7 billion by 2030. The analyst identifies massive market opportunities, with the global mechanical ventilators market expected to reach $20.69 billion by 2034. Inspira's flagship INSPIRA ART500 system in development aims to disrupt this market by providing respiratory support through direct blood oxygenation rather than forcing air into damaged lungs. Inspira has established strong intellectual property protection with multiple U.S. patents and novel patent claims protecting its core technologies. The company is executing a strategic approach of securing FDA clearance for individual components before integrating them into comprehensive systems. When comparing Inspira to similar medical device companies, the analyst found the stock trades at significant discounts despite having FDA-cleared technology already treating patients. The $2 price target reflects confidence in the company's ability to capitalize on its early commercial success and expand into the massive mechanical ventilation market. The analyst concludes that Inspira may represents a unique opportunity, combining proven FDA-cleared technology with substantial market opportunity and attractive valuation metrics in the high-growth medical device sector. Recent News from Inspira: Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing * Legal Disclaimer & Disclosure: Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by the Wall Street Wire platform & media network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This article contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire, which includes a monthly fee of five thousand US dollars paid in cash via bank transfer in return for promotional content and distribution services. The operators also receive additional fees for non promotional advisory and data services. Inspira Technologies did not necessarily review or approve this content prior to publication. Please review the full disclaimers and compensation disclosures here which include further details: redditwire.com/terms. We are not responsible for third party analyst price targets or market estimates are refer to them based on publicly availble reports. Additional or competing price target may exist and readers are advised to refer to the full report and its respective disclaimers and disclosures. Contact Details Wall Street Wire Editorial Desk media.globalmarkets@gmail.com

June 02, 2025 09:19 AM Eastern Daylight Time

12345 ... 697